Cargando…
Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study
We set out to identify factors of non-compliance with a protocol for the oral administration of misoprostol 25 µg (Angusta(®)) every 2 h (up to eight tablets), for the induction of labor (IOL). We conducted a retrospective study on IOL at term, on singleton pregnancies from 2019 to 2021, in a univer...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964196/ https://www.ncbi.nlm.nih.gov/pubmed/36836056 http://dx.doi.org/10.3390/jcm12041521 |
_version_ | 1784896443004223488 |
---|---|
author | Pambet, Mathilde Delabaere, Amélie Figuier, Claire Lambert, Céline Comptour, Aurélie Rouzaire, Marion Gallot, Denis |
author_facet | Pambet, Mathilde Delabaere, Amélie Figuier, Claire Lambert, Céline Comptour, Aurélie Rouzaire, Marion Gallot, Denis |
author_sort | Pambet, Mathilde |
collection | PubMed |
description | We set out to identify factors of non-compliance with a protocol for the oral administration of misoprostol 25 µg (Angusta(®)) every 2 h (up to eight tablets), for the induction of labor (IOL). We conducted a retrospective study on IOL at term, on singleton pregnancies from 2019 to 2021, in a university hospital. The study included 195 patients, comprising 144 compliant protocols. Pain was statistically more frequent in the non-compliance group (92.2% vs. 62.5%, p < 0.001), and when a midwife was unavailable (15.7% vs. 0.7%, p < 0.001). A multivariable analysis found factors of good response (defined as going into labor before the administration of the median number of tablets, i.e., six) to be an indication for PROM (OR: 12.03, 95% CI: 5.42–26.71), and gestational age at induction (OR: 1.54, 95% CI: 1.19–2.01), independently of BMI, initial Bishop score, and parity. Patients with pain who were able to follow the protocol delivered 9 h earlier than patients with pain who interrupted the protocol and 16 h earlier than patients who experienced no pain. We identified two key elements that favored compliance: (i) providing the next tablet in advance; and (ii) offering patients early epidural analgesia when in pain in order to continue the protocol and go into labor promptly. |
format | Online Article Text |
id | pubmed-9964196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99641962023-02-26 Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study Pambet, Mathilde Delabaere, Amélie Figuier, Claire Lambert, Céline Comptour, Aurélie Rouzaire, Marion Gallot, Denis J Clin Med Article We set out to identify factors of non-compliance with a protocol for the oral administration of misoprostol 25 µg (Angusta(®)) every 2 h (up to eight tablets), for the induction of labor (IOL). We conducted a retrospective study on IOL at term, on singleton pregnancies from 2019 to 2021, in a university hospital. The study included 195 patients, comprising 144 compliant protocols. Pain was statistically more frequent in the non-compliance group (92.2% vs. 62.5%, p < 0.001), and when a midwife was unavailable (15.7% vs. 0.7%, p < 0.001). A multivariable analysis found factors of good response (defined as going into labor before the administration of the median number of tablets, i.e., six) to be an indication for PROM (OR: 12.03, 95% CI: 5.42–26.71), and gestational age at induction (OR: 1.54, 95% CI: 1.19–2.01), independently of BMI, initial Bishop score, and parity. Patients with pain who were able to follow the protocol delivered 9 h earlier than patients with pain who interrupted the protocol and 16 h earlier than patients who experienced no pain. We identified two key elements that favored compliance: (i) providing the next tablet in advance; and (ii) offering patients early epidural analgesia when in pain in order to continue the protocol and go into labor promptly. MDPI 2023-02-14 /pmc/articles/PMC9964196/ /pubmed/36836056 http://dx.doi.org/10.3390/jcm12041521 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pambet, Mathilde Delabaere, Amélie Figuier, Claire Lambert, Céline Comptour, Aurélie Rouzaire, Marion Gallot, Denis Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study |
title | Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study |
title_full | Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study |
title_fullStr | Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study |
title_full_unstemmed | Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study |
title_short | Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study |
title_sort | factors of non-compliance with a protocol for oral administration of misoprostol (angusta(®)) 25 micrograms to induce labor: an observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964196/ https://www.ncbi.nlm.nih.gov/pubmed/36836056 http://dx.doi.org/10.3390/jcm12041521 |
work_keys_str_mv | AT pambetmathilde factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy AT delabaereamelie factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy AT figuierclaire factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy AT lambertceline factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy AT comptouraurelie factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy AT rouzairemarion factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy AT gallotdenis factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy |